Nova Biologics
Nova Biologics, a leading name in the biotechnology sector, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2005, the company has established itself as a pioneer in the development of innovative biologics, focusing on advanced therapeutic solutions for various medical conditions. Specialising in the production of high-quality monoclonal antibodies and recombinant proteins, Nova Biologics distinguishes itself through its commitment to rigorous quality control and cutting-edge research methodologies. The company has achieved significant milestones, including collaborations with major pharmaceutical firms and contributions to groundbreaking clinical trials. With a strong market position, Nova Biologics is recognised for its expertise in biologics manufacturing and its dedication to advancing healthcare through science. The company continues to push the boundaries of biotechnology, making a meaningful impact in the industry.
DitchCarbon Score
How does Nova Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nova Biologics's score of 3 is lower than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nova Biologics's reported carbon emissions
Nova Biologics, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without concrete figures or commitments, it is challenging to assess their climate impact or initiatives. However, the company may still be engaged in industry-standard practices aimed at reducing carbon footprints, such as improving energy efficiency and exploring sustainable materials. As the climate landscape evolves, it is essential for organisations like Nova Biologics to establish measurable targets and transparent reporting to contribute effectively to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nova Biologics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
